Empagliflozin
- PDF / 169,535 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 91 Downloads / 181 Views
1 S
Ketoacidosis: case report A 68-year-old man developed ketoacidosis during treatment with empagliflozin for diabetes mellitus. The man presented with a history of diabetes mellitus. He underwent colectomy surgery and suffered from abdominal pain and nausea for the following 10 days. He had been receiving antidiabetic therapy with empagliflozin [route and dosage not stated] which was stopped until day 5 after the surgery. Subsequently, nutrition and weaning was started on day 5 and day 6 respectively. Blood gases showed metabolic acidosis: PCO2 20.3 mm Hg, pH 7.38, BE [sic.] -11.63 mmol/l, bicarbonate 12 mmol/l, glucose 7 mmol/l and lactate 1.6 mmol/l. Despite of normal blood glucose level, a ketonuria was observed, and he was diagnosed with ketoacidosis [duration of treatment to reaction onset not stated]. After analysis, it was found that empagliflozin in times of catabolism and fasting can cause these symptoms. The man’s treatment with empagliflozin was discontinued, and he was initiated on insulin. His symptoms resolved within 3 days, and he was discharged from the ICU on day 17. He was prescribed not to use SGLT2-inhibitors again. Heiden AM, et al. Case report: Modern antidiabetic therapie causes ketoacidosis. Critical Care 24 (Suppl. 1): no pagination abstr. P263, 24 Mar 2020. Available from: URL: 803516033 http://doi.org/10.1186/s13054-020-2772-3 [abstract]
0114-9954/20/1831-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 21 Nov 2020 No. 1831
Data Loading...
